V0627

Valinomycin

≥98% (TLC), ≥90% (HPLC)

• Synonym(s): Cyclo(L-Val-D-HyIva-D-Val-L-Lac-)₃: HyIva = α-Hydroxyisovaleric acid, Lac = Lactic acid
• Empirical Formula (Hill Notation): C₅₄H₉₀N₆O₁₈
• CAS Number: 2001-95-8
• Molecular Weight: 1111.32
• Beilstein: 78657
• EC Number: 217-896-6
• MDL number: MFCD00005114
• UNSPSC Code: 12352200
• PubChem Substance ID: 24900697
• NACRES: NA.77

Properties

• Quality Level: 300
• Assay: ≥90% (HPLC); ≥98% (TLC)
• form: powder
• storage condition: (Keep container tightly closed in a dry and well-ventilated place.)
• color: white
• solubility: DMSO: ≥50 mg/mL; H₂O: insoluble
• antibiotic activity spectrum: Gram-positive bacteria; parasites; viruses
• Mode of action: cell membrane | interferes
• storage temp.: 2-8°C
• SMILES string: CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](NC(=O)[C@H](OC(=O)[C@@H](NC(=O)[C@H](C)OC(=O)[C@H](NC(=O)[C@H](OC(=O)[C@@H](NC(=O)[C@H](C)OC(=O)[C@H](NC(=O)[C@H](OC1=O)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C
• InChI: 1S/C54H90N6O18/c1-22(2)34-49(67)73-31(19)43(61)55-38(26(9)10)53(71)77-41(29(15)16)47(65)59-36(24(5)6)51(69)75-33(21)45(63)57-39(27(11)12)54(72)78-42(30(17)18)48(66)60-35(23(3)4)50(68)74-32(20)44(62)56-37(25(7)8)52(70)76-40(28(13)14)46(64)58-34/h22-42H,1-21H3,(H,55,61)(H,56,62)(H,57,63)(H,58,64)(H,59,65)(H,60,66)/t31-,32-,33-,34-,35+,36+,37-,38-,39-,40+,41+,42+/m0/s1
• InChI key: FCFNRCROJUBPLU-RPUZOQEISA-N

Description

General description

Chemical structure: peptide

Valinomycin is a cyclic peptide, which contains d-valine, d-α-hydroxyvaleric acid, l-valine, and l-lactic acid in the sequential order of cyclo-[(l-Val-d-Hyv-d-Val-l-Lac)₃].

Valinomycin, a nonribosomal peptide (NRP), is proposed to have a structure of a 24-membered cyclic peptide cyclo-(d-α-hydroxyisovaleryl-d-valyl-l-lactyl-l-valyl)2. It exhibits antitumor properties and plays a major role as a mitophagy activator. Initially isolated as an antibiotic compound, valinomycin has demonstrated antibacterial activity against Mycobacterium tuberculosis. Moreover, it has been identified as a potent antiviral agent against a wide spectrum of viruses, including human coronavirus, bunyavirus, enterovirus, and flavivirus.

Application

Valinomycin has been used:

• to equilibrate intracellular pH and extracellular pH of 5 (and 6-)-carboxyfluorescein succinimidyl ester (cFSE) in Escherichia coli strain B23
• as an ionophore to equilibrate intracellular pH and extracellular pH of lactic acid bacteria (LAB) strains
• to establish the desired pH for acid-base transition and formation of K⁺-valinomycin diffusion potential

Biochem/physiol Actions

K⁺-selective ionophoric cyclodepsipeptide; potassium ionophore which uncouples oxidative phosphorylation, induces apoptosis in murine thymocytes, inhibits NGF-induced neuronal differentiation and antagonizes ET-induced vasoconstriction.

Valinomycin selectively transfers alkali metal ions via biological and synthetic membranes. The formation of a metal ion-peptide complex contributes to this ion-transporting. Valinomycin can create stable complexes with potassium, rubidium, and cesium (K⁺, Rb⁺, and Cs⁺) .

Packaging

10MG,25MG,100MG,500MG

Other Notes

Keep container tightly closed in a dry and well-ventilated place.

Safety Information

• Pictograms: GHS06
• Signal Word: Danger
• Hazard Statements: H300 + H310
• Precautionary Statements: P262 - P264 - P280 - P301 + P310 - P302 + P352 + P310 - P361 + P364
• Hazard Classifications: Acute Tox. 1 Dermal - Acute Tox. 1 Oral
• Storage Class Code: 6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
• WGK: WGK 3
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Gloves